The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises
- PMID: 32694387
- PMCID: PMC7680716
- DOI: 10.1097/j.pain.0000000000001939
The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises
Abstract
The current International Association for the Study of Pain (IASP) definition of pain as "An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage" was recommended by the Subcommittee on Taxonomy and adopted by the IASP Council in 1979. This definition has become accepted widely by health care professionals and researchers in the pain field and adopted by several professional, governmental, and nongovernmental organizations, including the World Health Organization. In recent years, some in the field have reasoned that advances in our understanding of pain warrant a reevaluation of the definition and have proposed modifications. Therefore, in 2018, the IASP formed a 14-member, multinational Presidential Task Force comprising individuals with broad expertise in clinical and basic science related to pain, to evaluate the current definition and accompanying note and recommend whether they should be retained or changed. This review provides a synopsis of the critical concepts, the analysis of comments from the IASP membership and public, and the committee's final recommendations for revisions to the definition and notes, which were discussed over a 2-year period. The task force ultimately recommended that the definition of pain be revised to "An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage," and that the accompanying notes be updated to a bulleted list that included the etymology. The revised definition and notes were unanimously accepted by the IASP Council early this year.
Copyright © 2020 International Association for the Study of Pain.
Conflict of interest statement
Conflict of Interests:
None of the authors have expressed conflicts directly related to this manuscript. SNR is a consultant for Allergan, Lexicon Pharmaceuticals, Inc., and is a co-investigator in a grant from Medtronic, Inc. NBF is part of the IMI (Innovative Medicines Initiative) project PainCare, an EU public-private consortium, and the companies involved are Grunenthal, Bayer, Eli Lilly, Esteve, and Teva. NBF has been a consultant for Mitsubishi Tanabe Pharma, Merck, Almirall, and NeuroPN. MR has received research grant funding from Merck.
Figures
Comment in
-
Four decades later: what's new, what's not in our understanding of pain.Pain. 2020 Sep 1;161(9):1943-1944. doi: 10.1097/j.pain.0000000000001991. Pain. 2020. PMID: 32694379 No abstract available.
References
-
- Alcock MM. Defining pain: past, present, and future. Pain 2017;158:761–2. - PubMed
-
- Anand KJ, Craig KD. New perspectives on the definition of pain. Pain 1996;67:3–6. - PubMed
-
- Anand KJS, Rovnaghi C, Walden M, Churchill J. Consciousness, behavior, and clinical impact of the definition of pain. Pain Forum 1999;8:64–73.
-
- Aydede M Defending the IASP definition of pain. Monist 2017;100:439–64.
Publication types
MeSH terms
Grants and funding
- R01 AR070875/AR/NIAMS NIH HHS/United States
- P30 AG064201/AG/NIA NIH HHS/United States
- R01 AR073187/AR/NIAMS NIH HHS/United States
- R01 NS097221/NS/NINDS NIH HHS/United States
- UG3 AR076387/AR/NIAMS NIH HHS/United States
- R01 AG058702/AG/NIA NIH HHS/United States
- U24 AT009676/AT/NCCIH NIH HHS/United States
- U24 AT010961/AT/NCCIH NIH HHS/United States
- R01 NS026363/NS/NINDS NIH HHS/United States
- U24 NR014637/NR/NINR NIH HHS/United States
- U2C NR014637/NR/NINR NIH HHS/United States
- U24 NS112873/NS/NINDS NIH HHS/United States
- UG1 CA189824/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical